Inspiration Healthcare Group plc Announces Appointment of Louise Marie Janssen-Counotte as Non-Executive Director - Marketscreener.com
| ACARIX Stock | SEK 0.32 0.01 3.03% |
About 62% of Acarix AS's investor base is looking to short. The analysis of current outlook of investing in Acarix AS suggests that many traders are alarmed regarding Acarix AS's prospects. The current market sentiment, together with Acarix AS's historical and current headlines, can help investors time the market. In addition, many technical investors use Acarix AS stock news signals to limit their universe of possible portfolio assets.
Acarix |
Inspiration Healthcare Group plc Announces Appointment of Louise Marie Janssen-Counotte as Non-Executive Director Marketscreener.com
Read at news.google.com
 |
Acarix AS Fundamental Analysis
We analyze Acarix AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acarix AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acarix AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Acarix AS is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Acarix AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Acarix AS stock to make a market-neutral strategy. Peer analysis of Acarix AS could also be used in its relative valuation, which is a method of valuing Acarix AS by comparing valuation metrics with similar companies.
Peers
Acarix AS Related Equities
| BIOVIC-B | Biovica International | 3.89 | ||||
| SANION | Saniona AB | 3.56 | ||||
| CANTA | Cantargia | 2.69 | ||||
| EXPRS2 | ExpreS2ion Biotech | 3.32 |
Complementary Tools for Acarix Stock analysis
When running Acarix AS's price analysis, check to measure Acarix AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acarix AS is operating at the current time. Most of Acarix AS's value examination focuses on studying past and present price action to predict the probability of Acarix AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acarix AS's price. Additionally, you may evaluate how the addition of Acarix AS to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |